Bluejay Diagnostics shares surge 23.77% premarket after $4.5M private placement and expanded SanyoSeiko partnership.

Bluejay Diagnostics (NASDAQ:BJDX) surged 23.77% in premarket trading following two key announcements on October 9–10, 2025. The company closed a $4.5 million private placement at-the-market under Nasdaq rules, providing capital for FDA approval and R&D activities. Simultaneously, it expanded its strategic partnership with SanyoSeiko to advance the commercialization of its Symphony platform, a critical step for scaling its diagnostic solutions. These developments signal progress in product development and market readiness, aligning with the stock’s sharp premarket increase. The funding and partnership strengthen Bluejay’s ability to execute its growth strategy, particularly in regulatory and commercial milestones, which are pivotal for a biotech firm in its development phase.